| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $169K | +38.5% | +81.7% |
| SG&A Expense | $151K | +65.9% | +143.5% |
| Operating Income | -$320K | -50.2% | -106.5% |
| Net Income | -$266K | +19.9% | -112.9% |
| EPS (Basic) | -$0.05 | +37.5% | -110.2% |
| EPS (Diluted) | -$0.05 | +37.5% | -110.2% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $159K | -34.0% | +24.2% |
| Accounts Receivable | $20K | +400.0% | — |
| Current Assets | $231K | -14.1% | -28.5% |
| Total Assets | $569K | -7.6% | -28.1% |
| Total Liabilities | $3.7M | -2.9% | +11.7% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$482K | -460.5% | — |
| Capital Expenditures | $0 | — | — |
| Investing Cash Flow | $5K | — | — |
| Financing Cash Flow | $540K | — | — |
| Free Cash Flow | -$482K | — | — |
| -$3.2M |
| +0.1% |
| -14.3% |